ELI LILLY AND COMPANY (LLY) Current Ratio
- Current ratio · latest quarter: Value 1.35×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.35× | Current assets / current liabilities. $64.67B ÷ $47.74B ≈ 1.35× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 64.67B USD | Assets, Current |
| Current obligations | 47.74B USD | Liabilities, Current |
| Cash and equivalents | 8.95B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Available-for-sale Securities, Current |
| Customer receivables | 20.08B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 16.79B USD | Inventory, Net |
| Payables | 6.11B USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $64.67B | $47.74B | $8.95B | (m) | $20.08B | $16.79B | $6.11B | (m) | 1.35× |
| 2026-03-31 | $54.84B | $36.63B | $5.28B | (m) | $18.43B | $14.53B | $5.03B | (m) | 1.50× |
| 2025-12-31 | $55.63B | $35.23B | $7.27B | (m) | $17.76B | $13.74B | $5.38B | (m) | 1.58× |
| 2025-09-30 | $62.07B | $40.14B | $9.79B | (m) | $16.11B | $12.18B | $4.26B | (m) | 1.55× |
| 2025-06-30 | $49.85B | $39.02B | $3.38B | (m) | $14.17B | $11.01B | $4.08B | (m) | 1.28× |
| 2025-03-31 | $41.26B | $30.07B | $3.09B | (m) | $12.04B | $9.31B | $3.44B | (m) | 1.37× |
| 2024-12-31 | $32.74B | $28.38B | $3.27B | (m) | $11.01B | $7.59B | $3.23B | (m) | 1.15× |
| 2024-09-30 | $31.42B | $24.67B | $3.37B | (m) | $10.29B | $7.46B | $2.89B | (m) | 1.27× |
| 2024-06-30 | $30.20B | $27.12B | $3.22B | (m) | $11.03B | $6.48B | $2.92B | (m) | 1.11× |
| 2024-03-31 | $25.19B | $18.60B | $2.46B | (m) | $7.89B | $6.10B | $2.47B | (m) | 1.35× |
| 2023-12-31 | $25.73B | $27.29B | $2.82B | (m) | $9.09B | $5.77B | $2.60B | (m) | 0.94× |
| 2023-09-30 | $23.01B | $22.00B | $2.38B | (m) | $8.17B | $4.90B | $2.44B | (m) | 1.05× |
| 2023-06-30 | $21.33B | $18.91B | $2.69B | (m) | $7.52B | $4.80B | $2.47B | (m) | 1.13× |
| 2023-03-31 | $20.81B | $16.01B | $3.55B | (m) | $7.53B | $4.54B | $2.02B | (m) | 1.30× |
| 2022-12-31 | $18.03B | $17.14B | $2.07B | (m) | $6.90B | $4.31B | $1.93B | (m) | 1.05× |
| 2022-09-30 | $17.64B | $15.65B | $2.62B | (m) | $6.72B | $3.83B | $1.68B | (m) | 1.13× |
| 2022-06-30 | $17.12B | $15.62B | $2.62B | (m) | $6.36B | $3.90B | $1.66B | (m) | 1.10× |
| 2022-03-31 | $16.96B | $13.39B | $2.46B | (m) | $6.32B | $3.89B | $1.43B | (m) | 1.27× |
| 2021-12-31 | $18.45B | $15.05B | $3.82B | (m) | $6.67B | $3.89B | $1.67B | (m) | 1.23× |
| 2021-09-30 | $17.81B | $13.68B | $3.79B | (m) | $5.91B | $3.91B | $1.57B | (m) | 1.30× |
| 2021-06-30 | $17.30B | $15.09B | $3.22B | (m) | $5.83B | $3.82B | $1.60B | (m) | 1.15× |
| 2021-03-31 | $16.60B | $11.71B | $3.00B | (m) | $5.59B | $3.66B | $1.64B | (m) | 1.42× |
| 2020-12-31 | $17.46B | $12.48B | $3.66B | (m) | $5.88B | $3.98B | $1.61B | (m) | 1.40× |
| 2020-09-30 | $16.24B | $11.98B | $3.60B | (m) | $4.89B | $3.56B | $1.43B | (m) | 1.36× |
| 2020-06-30 | $14.58B | $11.99B | $2.37B | (m) | $4.83B | $3.31B | $1.25B | (m) | 1.22× |
| 2020-03-31 | $13.99B | $12.61B | $1.70B | (m) | $5.11B | $3.10B | $1.21B | (m) | 1.11× |
| 2019-12-31 | $13.71B | $11.78B | $2.34B | (m) | $4.55B | $3.19B | $1.41B | (m) | 1.16× |
| 2019-09-30 | $12.66B | $10.83B | (m) | (m) | $4.44B | $3.10B | $1.11B | (m) | 1.17× |
| 2019-06-30 | $13.45B | $11.86B | $2.29B | (m) | $4.61B | $3.18B | $1.20B | (m) | 1.13× |
| 2019-03-31 | $12.60B | $11.24B | $2.04B | (m) | $4.20B | $3.06B | $1.17B | (m) | 1.12× |
| 2018-12-31 | $20.55B | $11.89B | $7.32B | (m) | $4.59B | $3.10B | $1.21B | (m) | 1.73× |
| 2018-09-30 | $20.69B | $10.83B | $8.96B | (m) | $4.86B | $4.12B | $1.28B | (m) | 1.91× |
| 2018-06-30 | $18.33B | $13.06B | $6.82B | (m) | $4.82B | $4.16B | $1.32B | (m) | 1.40× |
| 2018-03-31 | $16.26B | $11.55B | $3.08B | (m) | $4.50B | $4.63B | $1.27B | (m) | 1.41× |
| 2017-12-31 | $19.20B | $14.54B | $6.21B | (m) | $3.98B | $3.40B | $1.21B | (m) | 1.32× |
| 2017-09-30 | $17.43B | $12.67B | $3.72B | (m) | $4.40B | $4.41B | $1.20B | (m) | 1.38× |
| 2017-06-30 | $15.75B | $11.29B | $3.07B | (m) | $4.35B | $4.35B | $1.26B | (m) | 1.39× |
| 2017-03-31 | $12.98B | $10.45B | $2.62B | (m) | $4.02B | $4.04B | $1.22B | (m) | 1.24× |
| 2016-12-31 | $15.10B | $10.99B | $4.58B | (m) | $4.03B | $3.56B | $1.35B | (m) | 1.37× |
| 2016-09-30 | $13.39B | $8.27B | $3.49B | (m) | $3.85B | $3.88B | $1.16B | (m) | 1.62× |
| 2016-06-30 | $12.98B | $8.40B | $3.24B | (m) | $3.95B | $3.76B | $1.21B | (m) | 1.54× |
| 2016-03-31 | $11.71B | $7.34B | $2.31B | (m) | $3.62B | $3.74B | $1.15B | (m) | 1.60× |
| 2015-12-31 | $12.57B | $8.23B | $3.67B | (m) | $3.51B | $3.45B | $1.34B | (m) | 1.53× |
| 2015-09-30 | $12.57B | $8.30B | $3.24B | (m) | $3.40B | $3.42B | $1.18B | (m) | 1.51× |
| 2015-06-30 | $12.35B | $8.23B | $3.32B | (m) | $3.35B | $3.29B | $1.15B | (m) | 1.50× |
| 2015-03-31 | $11.74B | $8.34B | $3.06B | (m) | $3.14B | $2.98B | $1.18B | (m) | 1.41× |
| 2014-12-31 | $11.93B | $9.74B | $3.87B | (m) | $3.23B | $2.74B | $1.13B | (m) | 1.22× |
| 2014-09-30 | $12.11B | $7.57B | $3.17B | (m) | $3.05B | $2.84B | $1.02B | (m) | 1.60× |
| 2014-06-30 | $13.16B | $7.42B | $3.77B | (m) | $3.19B | $3.19B | $1.12B | (m) | 1.77× |
| 2014-03-31 | $13.04B | $6.63B | $3.89B | (m) | $3.00B | $2.97B | $1.15B | (m) | 1.97× |
| 2013-12-31 | $13.10B | $8.92B | $3.83B | (m) | $3.43B | $2.93B | $1.12B | (m) | 1.47× |
| 2013-09-30 | $13.20B | $8.08B | $4.37B | (m) | $3.44B | $2.97B | $1.25B | (m) | 1.63× |
| 2013-06-30 | $12.64B | $8.41B | $3.79B | (m) | $3.58B | $2.73B | $1.14B | (m) | 1.50× |
| 2013-03-31 | $12.33B | $7.59B | $3.94B | (m) | $3.44B | $2.58B | $974.40M | (m) | 1.62× |
| 2012-12-31 | $13.04B | $8.39B | $4.02B | (m) | $3.34B | $2.64B | $1.19B | $11.90M | 1.55× |
| 2012-09-30 | $14.04B | $6.96B | $5.32B | (m) | $3.27B | $2.55B | $1.33B | (m) | 2.02× |
| 2012-06-30 | $12.31B | $6.61B | $4.35B | (m) | $3.18B | $2.32B | $1.20B | (m) | 1.86× |
| 2012-03-31 | $12.60B | $6.55B | $4.12B | (m) | $3.40B | $2.42B | $1.25B | (m) | 1.92× |
| 2011-12-31 | $14.25B | $8.93B | $5.92B | (m) | $3.60B | $2.30B | $1.13B | $1.52B | 1.60× |
| 2011-09-30 | $14.57B | $8.22B | $6.60B | (m) | $3.53B | $2.51B | $1.15B | (m) | 1.77× |
| 2011-06-30 | $14.95B | $8.62B | $6.11B | (m) | $3.83B | $2.87B | $1.19B | (m) | 1.73× |
| 2011-03-31 | $15.35B | $7.65B | $6.51B | (m) | $3.69B | $2.77B | $1.18B | (m) | 2.01× |
| 2010-12-31 | $14.84B | $6.93B | $5.99B | (m) | $3.49B | $2.52B | $1.07B | $18.20M | 2.14× |
| 2010-09-30 | $14.18B | $6.10B | $5.91B | (m) | $3.34B | $2.68B | $1.03B | (m) | 2.33× |
| 2010-06-30 | $12.47B | $6.32B | $5.16B | (m) | $3.07B | $2.17B | $950.30M | (m) | 1.97× |
| 2010-03-31 | $12.25B | $5.66B | $4.73B | (m) | $3.19B | $2.47B | $964.00M | (m) | 2.17× |
| 2009-12-31 | $12.49B | $6.57B | $4.46B | (m) | $3.34B | $2.85B | $968.10M | $-20.30M | 1.90× |
| 2009-09-30 | $11.81B | $6.07B | $3.85B | (m) | $3.02B | $3.13B | $887.70M | (m) | 1.95× |
| 2009-06-30 | $10.94B | $6.99B | $3.32B | (m) | $2.84B | $3.00B | $918.60M | (m) | 1.56× |
| 2008-12-31 | $12.45B | $13.11B | $5.50B | (m) | $2.78B | $2.49B | $885.80M | (m) | 0.95× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |